Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

OCRX 7.47 +0.26 (3.61%)
price chart
Ocera Therapeutics (OCRX) Shares March Higher, Can It Continue?
Investors certainly have to be happy with Ocera Therapeutics Inc (OCRX - Snapshot Report) and its short term performance. After all, the stock has jumped by 8.2% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well.
Related articles »  
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4%
Ocera Therapeutics, Inc. (OCRX - Snapshot Report) was a big mover last session with its shares rising over 9% on the day.
Ocera up again today (OCRX)  Seeking Alpha
Ocera Therapeutics (OCRX) Worth Watching: Stock Up 9.4% - Tale of the Tape  Nasdaq
Related articles »  
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics Well-Capitalized After The Merger
Ocera licensed the compound from Kureha Corporation of Japan in 2005. AST-120 has been used chronically by over 360,000 patients and studied in over 3,000 patients worldwide.
Investor Stock Alert on Price Target:Ocera Therapeutics Inc , Actua Corporation
Ocera Therapeutics Inc (NASDAQ:OCRX) should head towards $21.5 per share according to 2 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $17 per share.
Biotech Bears in Focus: Avalanche Biotechnologies (NASDAQ:AAVL), Ocera ...  Property Mentor
Related articles »  
Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference
Ocera Therapeutics, Inc. OCRX, +15.15% a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the Stifel 2014 Healthcare Conference being held ...
Related articles »  
Ocera Therapeutics Announces Appointment of Gaurav Aggarwal, MD, as Chief ...
PALO ALTO, Calif., May 2, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics (Nasdaq:OCRX) today announced that Gaurav Aggarwal, M.D.
Related articles »  
Ocera Therapeutics Upgraded to "Outperform" by Zacks (OCRX)
Ocera Therapeutics Inc logo Zacks upgraded shares of Ocera Therapeutics (NASDAQ:OCRX) from a neutral rating to an outperform rating in a research note released on Wednesday morning.
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 13th Annual BIO ...
Related articles »  
Ocera Therapeutics: A Potential Multibagger Biopharmaceutical Company
Ocera Therapeutics [Nasdaq: (NASDAQ:OCRX)] announced the initiation of its phase 2b double blind, controlled, randomized clinical trial in early January 2014.
Related articles »